Novopulmon Novolizer 200 mikrog/annos inhalaatiojauhe Suomi - suomi - Fimea (Suomen lääkevirasto)

novopulmon novolizer 200 mikrog/annos inhalaatiojauhe

viatris oy - budesonide - inhalaatiojauhe - 200 mikrog/annos - budesonidi

Novopulmon Novolizer 400 mikrog/annos inhalaatiojauhe Suomi - suomi - Fimea (Suomen lääkevirasto)

novopulmon novolizer 400 mikrog/annos inhalaatiojauhe

viatris oy - budesonide - inhalaatiojauhe - 400 mikrog/annos - budesonidi

Comirnaty Euroopan unioni - suomi - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

Stocrin Euroopan unioni - suomi - EMA (European Medicines Agency)

stocrin

merck sharp & dohme b.v. - efavirentsi - hiv-infektiot - antiviraalit systeemiseen käyttöön - stocrin ilmoitetaan antiviraalinen yhdistelmähoito ihmisen-hi-virus-1 (hiv-1)-tartunnan saaneiden aikuisten, nuorten ja lasten kolme vuotta täyttäneille. stocrinia ei ole tutkittu riittävästi potilailla, joilla on pitkälle edennyt hiv-tauti eli potilailla, joiden cd4-arvo on < 50 solua/mm3, tai kun vika proteaasi-inhibiittori (pi)-sisältävät hoito-ohjelmat. vaikka ristiresistenssiä efavirentsin ja proteaasinestäjien kesken ei ole dokumentoitu, tällä hetkellä ei ole riittävästi tietoa tehoa myöhempää käyttöä pi-pohjainen yhdistelmä hoidon jälkeen epäonnistuminen hoito sisältää stocrinin.

Canesten 200 mg emätinpuikko, tabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

canesten 200 mg emätinpuikko, tabletti

bayer oy - clotrimazole - emätinpuikko, tabletti - 200 mg - klotrimatsoli

Canesten 20 mg/g emätinemulsiovoide Suomi - suomi - Fimea (Suomen lääkevirasto)

canesten 20 mg/g emätinemulsiovoide

bayer oy - clotrimazole - emätinemulsiovoide - 20 mg/g - klotrimatsoli

Voltaren Emulgel 11.6 mg/g geeli Suomi - suomi - Fimea (Suomen lääkevirasto)

voltaren emulgel 11.6 mg/g geeli

haleon denmark aps - diclofenac diethylamine - geeli - 11.6 mg/g - diklofenaakki

LESCOL 20 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

lescol 20 mg kapseli, kova

novartis finland oy - fluvastatinum natricum - kapseli, kova - 20 mg - fluvastatiini

LESCOL 40 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

lescol 40 mg kapseli, kova

novartis finland oy - fluvastatinum natricum - kapseli, kova - 40 mg - fluvastatiini

Repevax injektioneste, suspensio, esitäytetty ruisku Suomi - suomi - Fimea (Suomen lääkevirasto)

repevax injektioneste, suspensio, esitäytetty ruisku

sanofi pasteur europe - poliovirus type 1, inactivated, poliovirus type 2, inactivated, poliovirus type 3, inactivated, bordetella pertussis toxoid, adsorbed, bordetella pertussis filamentous haemagglutinin, adsorbed, bordetella pertussis pertactin, adsorbed, corynebacterium diphtheriae toxoid, adsorbed, clostridium tetani toxoid, adsorbed, bordetella pertussis fimbriae, adsorbed - injektioneste, suspensio, esitäytetty ruisku - kurkkumätä-